DNA sequencing gear maker Illumina (ILMN) struck strategic partnerships with several big drugmakers to develop a universal sequencing-based oncology test system for cancer diagnosis. Its initial partners for the project include AstraZeneca (AZN), Johnson & Johnson (JNJ)-owned Janssen Biotech and Sanofi (SNY). The system will be used to conduct clinical trials for specific cancer therapies and will help ID cancers that might respond to targeted therapies. Illumina shares fell0.5% to 172.09. AstraZeneca rose 3.1% to 73.19 and Sanofi rose 1.8% to 53.74.